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INTRODUCTION
Epithelial ovarian cancer (EOC) is the second most common gy-
necologic malignancy in developed countries, and accounts for 
more deaths than the remaining gynecologic cancers added 
together [1]. EOC can spread by intraperitoneal seeding, direct 
invasion, or through lymphatic or vascular circulation, and the 
peritoneal seeding is the most common route of dissemination [2].
In most women with EOC, the disease is not diagnosed until 
it is at an advanced stage. Primary cytoreductive surgery fol-
lowed by taxane/platinum-based adjuvant chemotherapy is 
considered the standard approach to these patients [3]. Some 
observers have noted that the maximal cytoreduction, corre-
lated to the minimal residual tumor mass after surgery, is one 
of the most powerful prognostic factors [4-6]. 
Imaging of the peritoneum has been routinely performed 
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Objective: To determine whether [
18F]FDG uptake on PET/CT imaging before surgical staging has prognostic significance in 
patients with epithelial ovarian cancer (EOC).
Methods: Patients with EOC were imaged with integrated PET/CT before surgical staging. Hypermetabolic lesions were 
measured as the standardized uptake value (SUV) in primary and metastatic tumors. SUV distribution was divided into 
two regions at the level of umbilicus, and the impact of the ratio between above and below umbilicus (SUVlocation ratio) on 
progression-free survival (PFS) was examined using Cox proportional hazards regression.
Results: Between January 2004 and December 2009, 55 patients with EOC underwent preoperative PET/CT. The median 
duration of PFS was 11 months (range, 3 to 43 months), and twenty (36.4%) patients experienced recurrence. In univariate 
analysis, high SUVlocation ratio (p=0.002; hazard ratio [HR], 1.974; 95% confidence interval [CI], 1.286 to 3.031) was significantly 
associated with recurrence. Malignant mixed mullerian tumor compared with endometrioid histology was also shown to have 
significance. In multivariate analysis, high SUVlocation ratio (p=0.005; HR, 2.418; 95% CI, 1.1315 to 4.447) and histology (serous, 
mucinous, and malignant mixed mullerian tumor compared with endometrioid type) were significantly associated with 
recurrence. Patients were categorized into two groups according to SUVlocation ratio (<0.3934 vs. ≥0.3934), and the Kaplan-Meier 
survival graph showed a significant difference in PFS between the groups (p=0.0021; HR, 9.47, log-rank test).
Conclusion: SUV distribution showed a significant association with recurrence in patients with EOC, and may be a useful 
predictor of recurrence.
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by means of contrast-enhanced CT, however, the sensitivity of 
this technique depends on the size and location of peritoneal 
implants. Moreover, anatomical imaging uses only size criteria 
and does not recognize the functional alterations that occur 
within tumor tissue. PET/CT using [
18F]FDG has been success-
fully employed to visualize enhanced glucose utilization in 
tumor tissues. PET/CT has been shown to identify primary 
tumors, regional lymph nodes, and distant metastases with 
high diagnostic accuracy for primary and recurrent EOC [7-
10]. These hybrid systems perform both PET and CT and co-
register images with an improvement of anatomic localization 
of intra- and extra-pelvic structures [11], as well as allowing 
the detection of distant supra-diaphragmatic metastases [12]. 
Several studies have shown that PET or PET/CT were useful for 
monitoring treatment response [13,14], detecting residual dis-
ease after completion of therapy [15,16], and detecting recur-
rent or metastatic lesions in EOC [8,17]. 
However, only limited information is currently available des-
cri  bing the role of PET/CT for the prediction of recurrence in 
EOC. This study evaluated the hypothesis that the pretreat-
ment metabolic activities measured by FDG uptake and its 
distribution will allow prediction of prognosis. The aim of this 
study was to evaluate the prognostic value of the distribution 
of FDG up  take on preoperative PET/CT scans in patients with 
EOC.
MATERIALS AND METHODS
1. Patient population 
This study was approved by our institutional review board. 
We retrospectively reviewed the tumor registry at our institu-
tion and identified all patients diagnosed with EOC between 
January 2004 and December 2009. All clinical, histological and 
imaging data of patients at our institution were collected and 
stored in a computerized database. Patients were required to 
have undergone an PET/CT study just before establishing a 
pathologic diagnosis, to have received no treatment before 
the study, and to have had at least 3 months of follow-up. 
Patients were excluded in the analysis if any of the following 
criteria were present: 1) a previous diagnosis of another malig-
nant disease or borderline tumor, 2) short follow-up duration 
less than 3 months, 3) primary treatment other than surgery 
such as neoadjuvant chemotherapy, 4) known allergy to con-
trast media, diabetes or other severe medical conditions. Tu-
mor histologic cell type, grade, stage at surgical staging, site 
of metastasis, and treatment were recorded from the patient’
s medical record. A stage after surgical staging was assigned 
according to the International Federation of Gynecology and 
Obstetrics (FIGO). 
2. PET/CT imaging
The patients were imaged using a dedicated PET/CT sys-
tem (Gemini, Philips Medical Systems, Andover, MA, USA). All 
patients were instructed to fast at least 4 hours prior to un-
dergoing PET/CT; 125 mL of a barium sulfate solution (Readi-
cat [1.3% weight-volume barium sulfate suspension]; E-Z-
EM, Westbury, NY, USA or EZCT [1.5% weight-volume barium 
sulfate suspension], Taejoon Pharm, Seoul, Korea) was admin-
istered orally 1 hour prior to imaging to opacify the bowel for 
the CT portion of the study, following methods described in 
our previous study [18]. PET/CT scans were obtained between 
1 day and 23 days (median, 5 days) before surgery. 
3. Image analysis
All images were interpreted and analyzed by two experien-
ced nuclear medicine physicians (HWK, KWK) with all available 
clinical information. The images were reviewed on an inter  ac-
ti  ve video display provided by the equipment manufacturer 
standardized uptake value (SUV)max was quantitatively used to 
determine FDG activity. Calculation of SUVmax was as follows: 
SUVmax
 =
 Cmax×TBW/IA (Cmax, activity concentration in the voxel 
of highest metabolic activity [Bq/mL]; TBW, total body weight 
(kg); IA, injected activity [kBq]). 
SUV distribution was divided into two regions at the level of the 
umbilicus, and the impact of the ratio between above and below 
the umbilicus (SUVlocation ratio
 =
 sum of SUV above umbilicus
 /
 sum 
of SUV below umbilicus) on recurrence was examined.
4. Treatment and follow-up
After the PET/CT scan and a definitive surgical staging, 50 
patients were treated with chemotherapy. Survival data were 
obtained from the tumor registry and verified on review of the 
medical records. 
5. Histological and clinical evaluation 
Recurrent disease was confirmed in all cases by either tissue 
biopsy or the demonstration of progressive disease by serial 
imaging studies such as CT, MRI, or PET/CT. Clinical proof of 
no recurrent disease consisted of a negative tissue biopsy and 
negative finings on serial follow-up imaging studies.
To confirm lesions detected on PET/CT imaging, CT- or ultra-
sound-guided biopsy was performed to obtain tissues for his-
tological evaluation in cases where it was considered neces-
sary for patient management. Progressive elevation of serum 
tumor marker (CA-125) accompanied by an increase in lesion 
size or the appearance of new lesions was considered disease 
recurrence. Hyun Hoon Chung, et al.
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6. Data analysis
With respect to SUVlocation ratio, receiver operating character-
istic (ROC) curve analysis was performed in order to determine 
the cutoff values for predicting recurrence. Progression-free 
survival (PFS) was calculated as the interval from the date of 
treatment completion to the first documented date of pro-
gression, or death whichever occurred first. Survival curves 
were constructed using the method of Kaplan and Meier. The 
Cox proportional hazards modeling used to identify indepen-
dent variables associated with recurrence. Results from the 
Cox models are expressed as hazard ratios (HRs) with 95% 
confidence intervals (CIs), and p<0.05 was considered the 
level of significance. The SPSS ver. 11.0 (SPSS Inc., Chicago, IL, 
USA) was used for the statistical analysis.
RESULTS
1. Characteristics of the patients 
Of the 337 patients diagnosed as EOC, 299 patients under-
went primary debulking surgery during the study period. 
There were 76 patients with a median age of 54 years (range, 
35 to 80 years) who met the inclusion criteria. A total of 55 pa-
tients underwent preoperative PET/CT scanning.
2. PET/CT and survival
Median follow-up time was 16 months (range, 3 to 50 months), 
and the median PFS duration was 11 months (range, 3 to 43 
months). Twenty (36.4%) patients experienced recurrence, and 
one patient died of disease. The 3-year PFS rate was 50.8%.
3. Cutoff value of SUVlocation ratio
Fig. 1 shows the ROC curve analyzing the SUVlocation ratio in 
PFS. Area under the curve (AUC) was 0.740 (p=0.004; 95% CI, 
0.607 to 0.873), and the value of 0.3934 was determined as 
the cutoff of SUVlocation ratio in this study, and patients were 
categorized into two groups according to the SUVlocation ratio 
(<0.3934 vs. ≥0.3934). Table 1 lists the descriptive statistics 
among demographic subgroups categorized by the cutoff 
SUVlocation ratio. Patient distribution was significantly differ-
ent according to FIGO stage (p=0.015), residual disease after 
surgery (p=0.017), and patients status (p=0.004) between the 
two groups categorized by the SUVlocation ratio. Table 2 lists the 
median PFS among groups categorized by the cutoff SUVlocation 
ratio. 
4. SUVlocation ratio and recurrence
Table 3 shows the results of the Cox proportional hazard 
analyses. In univariate analysis, high SUVlocation ratio (p=0.002; 
HR, 1.974; 95% CI, 1.286 to 3.031) was significantly associated 
with recurrence. Malignant mixed mullerian tumors (MMMT) 
compared with endometrioid histology was also shown to 
have significance. In multivariate analysis, high SUVdistribution ra-
tio (p=0.005; HR, 2.418; 95% CI, 1.1315 to 4.447), and histology 
(serous, p=0.031; mucinous, p=0.045; MMMT, p=0.003; com-
pared with endometrioid type) were significantly associated 
with recurrence. The Kaplan-Meier survival graph showed a 
significant difference in PFS between the groups categorized 
by SUVlocation ratio (Fig. 2). Survival difference between the two 
groups was statistically significant (p=0.0021, log-rank test). 
DISCUSSION
The purpose of the current study was to determine whether 
the preoperative metabolic tumor burden and its distribution 
as measured by the SUV have prognostic significance in pa-
tients with EOC. To the best of our knowledge, this is the first 
study reporting the prognostic value of preoperative PET/CT 
on predicting the risk of recurrence in patients with EOC. 
The principle finding was that the metabolic tumor burden 
in the upper abdomen measured as SUVlocation ratio on preop-
erative PET/CT was the most powerful significant prognostic 
factor for predicting recurrence in EOC. It is noteworthy that 
FIGO stage was not a significant prognostic factor for recur-
rence in this study. This may be due to the small number of 
patients enrolled, and the distribution of stage (most patients 
were stage III). We found that another tumor-related factor 
such as tumor histology was also a predictor of recurrence. 
Fig. 1. ROC curve analysis for de  ter  mi  na  tion of the cutoff value of the 
ratio of metabolic standardized uptake value (SUV) location (SUVlocation) 
ratio  according  to  anatomic  location  for  pre  dic  ting recurrence. The 
area under the ROC curve for discrimi  na  ting re  cu  rrence of [
18F]FDG 
PET/CT using the cutoff value of 0.3934 was 0.74 (p=0.004; 95% 
confidence interval, 0.607 to 0.873).FDG uptake and recurrence in ovarian cancer
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The results of the current study demonstrate the potential 
value of preoperative PET/CT in patients with preoperative 
SUVlocation ratio. We aim to perform more frequent and inten-
sive follow-up or prophylactic administration of consolidation 
treatment in these patients, and may individualize patient 
care according to the preoperative SUVlocation ratio.
In previous studies, the presence of residual tumor after pri-
mary surgery has been shown to be an independent prognos-
tic factor [19-23]. A Gynecologic Oncology Group (GOG) study 
demonstrated that patients with stage III disease presenting 
with large-volume ovarian cancer before undergoing optimal 
cytoreduction had a worse prognosis than patients found to 
have small-volume disease at the time of exploration [24]. 
The Scottish Randomized Trial in Ovarian Cancer (SCOTROC) 
showed that a clinically significant PFS benefit with optimal 
surgery among patients with stage IC to IV disease was limited 
to patients with less advanced disease [25].
Adding values of lesional SUVs may imply the importance 
of tumor burden, and it may depend on the number of meta-
static lesions without information of tumor volume. In this 
respect, we calculated the metabolic tumor volume (MTV) 
and performed analysis using the sum of MTVs. However, 
preoperative MTV was not an independent prognostic factor 
of recurrence in the current study (data not shown). Here, we 
hypothesized that the locus of the metastatic tumor burden 
would have prognostic importance. 
Table 1. Patient characteristics for epithelial ovarian cancer: comparison of groups categorized by the ratio of the location of hypermetabolism
Variable SUVlocation ratio
 <
 0.3934 SUVlocation ratio
 ≥
 0.3934 p-value* SUVlocation ratio
Age (yr) 54 (35-80) 53 (36-80) 0.431 54 (35-80)
FIGO stage 0.015
    I 5 (18.5) 1 (3.6) 0 (0-0.69)
    II 5 (18.5) 0 (0.0) 0 (0-0.12)
    III 17 (63.0) 26 (92.9) 0.55 (0-3.9)
    IV 0 (0.0) 1 (3.6) 0.98 
Histology 0.07
    Serous 12 (44.4) 22(78.6) 0.63 (0-3.1)
    Mucinous 2 (7.4) 0 (0.0) 0
    Endometrioid  7 (25.9) 3 (10.7) 0 (0-3.1)
    Clear cell  1 (3.7) 0 (0.0) 0
    Undifferentiated  2 (7.4) 1 (3.6) 0.35 (0.31-0.97)
    MMMT 1 (3.7) 2 (7.1) 0.57 (0-3.9)
    Transitional cell 2 (7.4)
CA-125 650 (8-4,620) 810 (3-43,530) 0.399 750 (3-43,530)
Grade 0.255
    1 4 (14.8) 1 (3.6) 0 (0-0.69)
    2 6 (22.2) 3 (10.7) 0 (0-0.66)
    3 16 (59.3) 22 (78.6) 0.56 (0-3.9)
    Unknown 1 (3.7) 2 (7.1) 0.60 (0.13-1.23)
Residual after surgery 0.017
    Yes 6 (22.2) 15 (53.6) 0.94 (0-3.9)
    No 21 (77.8) 13 (46.4) 0.18 (0-3.1)
Patient status 0.004
    NED 23 (85.2) 12 (42.9) 0.21 (0-3.1)
    AWD 4 (14.8) 15 (53.6) 0.66 (0-3.9)
    EXP 0 (0.0) 1 (3.6) 1.0 
Values are presented as mean (range) or number (%). All p-values result from a χ
2 test except for the variable of age and CA-125, in which a 
t-test was performed.
SUVmax, maximum standardized uptake value; FIGO, International Federation of Obstetrics and Gynecology; MMMT, malignant mixed müllerian 
tumor; NED, no evidence of disease; AWD, alive with disease; EXP, expired.Hyun Hoon Chung, et al.
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Table 2. Median progression-free survival among groups categorized by the ratio of the location of hypermetabolism
Variable
SUVlocation ratio
 <
 0.3934 SUVlocation ratio
 ≥
 0.3934 Overall
No. No. recur Median PFS 
(mo) No. No. recur Median PFS 
(mo) No. No. recur Median PFS 
(mo)
FIGO stage
    I 5 0 16.2 1 0 30.4 6 0 18.0
    II 5 0 10.4 0 0 5 0 10.4
    III 17 4 10.5 26 15 9.8 43 19 10.2
    IV 0 0 1 1 11.1 1 1 11.1
Histology
    Serous 12 3 10.3 22 13 10.7 34 16 10.5
    Mucinous 2 1 9.9 0 0 2 1 9.9
    Endometrioid 7 0 16.2 3 1 15.2 10 1 10.5
    Clear cell 1 0 19.8 0 0 1 0 19.8
    Undifferentiated  2 0 22.6 1 0 4.0 3 0 9.5
    MMMT 1 0 3.3 2 2 6.0 3 2 3.3
    Transitional cell 2 0 29.0 0 0 2 0 29.0
Grade 
    1 4 1 15.4 1 0 30.4 5 1 16.2
    2  6 0 14.8 3 2 11.1 9 2 13.6
    3 16 3 11.8 22 13 9.8 38 16 10.3
    Unknown 1 0 10.5 2 1 17.4 3 1 10.5
Residual after surgery
    Yes 6 2 8.7 15 8 10.8 21 10 9.8
    No 21 2 14.5 13 8 9.8 34 10 12.4
SUVmax, maximum standardized uptake value; PFS, progression-free survival; FIGO, International Federation of Obstetrics and Gynecology; MMMT, 
malignant mixed müllerian tumor.
Table 3. Results of analyses of prognostic factors for progression-free survival
Variable Test for favorable status Hazard ratio 95% confidence interval p-value
Univariate analysis
    Age 1.012 0.973-1.054 0.549
    FIGO stage Stage III-IV vs. stage I-II 33.774 0.450-2535.840 0.110
    Histology Serous vs. endometrioid 7.565 0.990-57.821 0.051
MMMT vs. endometrioid 46.067 3.793-555.432 0.003
    SUVmax (uncategorized) 0.997 0.979-1.016 0.764
    Serum CA-125 ≥298.5 vs. <298.5 2.423 0.702-8.361 0.161
    Residual tumor Yes vs. no 1.853 0.749-4.584 0.182
    SUVlocation ratio (uncategorized) 1.974 1.286-3.031 0.002
    Metabolic tumor volume ≥46.24 vs.  <46.24 2.421 0.917-6.391 0.074
Multivariate analysis .
    SUVlocation ratio (uncategorized) 2.418 1.315-4.447 0.005
    Histology Serous vs. endometrioid 10.639 1.237-91.494 0.031
MMMT vs. endometrioid 63.514 4.293-939.632 0.003
MMMT vs. mucinous 22.442 1.075-468.523 0.045
FIGO, International Federation of Obstetrics and Gynecology; SUVmax, maximum standardized uptake value; MMMT, malignant mixed müllerian 
tumor.FDG uptake and recurrence in ovarian cancer
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One of the main pitfalls of PET imaging is the non-invasive 
visualization of diffuse peritoneal carcinomatosis, with the tu-
mor spread through small implants on the peritoneal surface: 
the problem emanates from the reduced spatial resolution of 
PET imaging (5-6 mm) that makes it unable to visualize min-
ute tumor implants, as in miliary carcinomatosis.
We recognize several limitations of this study. Most nota-
bly is that it was a retrospective study performed at a single 
institution with a relatively small number of patients (n=55). 
There may have been selection bias. Not all patients with EOC 
underwent preoperative PET/CT during the study period. The 
physician’s attitude to PET/CT may have influenced the refer-
ral of patients in the retrospective study design. Hence, our 
findings may not be generalizable to all EOC patients, as only 
selected patients may have been referred to PET/CT scanning, 
and image acquisition and interpretation procedures will be 
different according to institutions. Additional standardized 
large prospective studies may be necessary to confirm the 
prognostic value of preoperative PET/CT in clinical practice. 
Secondly, we could not analyze the overall survival because 
there was only one case of disease-related death among the 
study population, and the study period was relatively short 
since PET/CT has only recently been introduced at our insti-
tution. We are preparing a prospective study to confirm the 
currently reported results, and eventually to determine if pre-
treatment PET/CT has predictive prognosis value.
Although this study has some limitations, it also demon-
strates unique and significant findings, because to the best of 
our knowledge no study published to date has demonstrated 
the prognostic significance of metabolic burden in patients 
with EOC. The findings of the current study have important 
implications for the management of patients with EOC; pa-
tients with high SUVlocation ratio in preoperative PET/CT scan 
should be closely monitored after treatment, or consolidation 
treatment after previously-planned therapy may be seriously 
considered. In addition, targeting molecular therapeutics us-
ing tumor metabolism might be proposed and be a candidate 
theme of future research in the treatment of EOC. 
In conclusion, preoperative SUVlocation ratio was a significant 
prognostic indicator for recurrence in patients with EOC, and 
may allow individualization of patient care. Further analysis 
with a larger patient population and longer follow-up is war-
ranted for confirmation of the findings of this study.
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